{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:22:08Z","timestamp":1787656928575,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001880","name":"STOP CANCER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA206911"],"award-info":[{"award-number":["R01CA206911"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejca.2021.05.035","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:39:16Z","timestamp":1625168356000},"page":"11-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Phase I\/II trial of palbociclib, pembrolizumab\u00a0and letrozole in patients with hormone receptor-positive metastatic breast cancer"],"prefix":"10.1016","volume":"154","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7440-8939","authenticated-orcid":false,"given":"Yuan","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Yost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colt A.","family":"Egelston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Padam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schmolze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary","family":"Presant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Sedrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Portnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.05.035_bib1","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"R77","key":"10.1016\/j.ejca.2021.05.035_bib2","article-title":"PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in\u00a0vitro","volume":"11","author":"Finn","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib3","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.035_bib4","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib5","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejca.2021.05.035_bib6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.035_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.035_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JGO.2016.008318","volume":"3","author":"Iwata","year":"2017","journal-title":"J Glob Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2021.05.035_bib10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2021.05.035_bib12","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1158\/1078-0432.CCR-18-0790","article-title":"Combination paclitaxel and palbociclib: results of a phase I trial in advanced breast cancer","volume":"25","author":"Clark","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib13","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1200\/JCO.2019.37.15_suppl.1016","article-title":"Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+\/HER2\u2212 advanced breast cancer postprogression on a CDK4\/6 inhibitor (TRINITI-1): efficacy, safety, and biomarker results","volume":"37","author":"Bardia","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib14","first-page":"1298","article-title":"PD-1 inhibitor promising in treatment of triple-negative breast cancer","volume":"11","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ejca.2021.05.035_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.035_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejca.2021.05.035_bib17","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib18","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1078-0432.CCR-10-0505","article-title":"Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells","volume":"16","author":"Vonderheide","year":"2010","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib19","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.035_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1200\/JCO.2018.36.15_suppl.1010","article-title":"Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer","volume":"36","author":"Barroso-Sousa","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.05.035_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2021.05.035_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib24","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.26797","article-title":"Clinical validation of the tempus xT next-generation targeted oncology sequencing assay","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.035_bib25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157368","article-title":"Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection","volume":"11","author":"Lehmann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2021.05.035_bib27","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.ejca.2021.05.035_bib28","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2021.05.035_bib29","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3389\/fonc.2019.00666","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors: potential implications and biomarkers for clinical practice","volume":"9","author":"McCartney","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","article-title":"ER\u03b1-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer","volume":"1","author":"Miller","year":"2011","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2021.05.035_bib31","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.035_bib32","article-title":"CDK4\/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy","volume":"8","author":"Lai","year":"2020","journal-title":"J Immunother Canc"},{"key":"10.1016\/j.ejca.2021.05.035_bib33","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1038\/s41598-018-25357-0","article-title":"Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism","volume":"8","author":"Du","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2021.05.035_bib34","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jnci\/djx268","article-title":"Immune infiltration in invasive lobular breast cancer","volume":"110","author":"Desmedt","year":"2018","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.035_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-018-1353-9","article-title":"Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients","volume":"24","author":"Mukai","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.05.035_bib37","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS19-P1-19-13","article-title":"Abstract P1-19-13: a phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo","volume":"80","author":"Krishnamurthy","year":"2020","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.035_bib38","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2020.38.15_suppl.1051","article-title":"A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): interim results","volume":"38","author":"Rugo","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib39","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.2016.69.0032","article-title":"Cell-cycle therapeutics come of age","volume":"35","author":"Ingham","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41416-018-0327-z","article-title":"The clinical role of the TME in solid cancer","volume":"120","author":"Giraldo","year":"2019","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.05.035_bib42","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.035_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw192","article-title":"Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer","volume":"109","author":"Bense","year":"2017","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.035_bib44","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12916-015-0431-3","article-title":"Relevance of tumor-infiltrating lymphocytes in breast cancer","volume":"13","author":"Dushyanthen","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2021.05.035_bib45","article-title":"Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4\/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer","volume":"9","author":"Egelston","year":"2021","journal-title":"J Immunother Canc"},{"key":"10.1016\/j.ejca.2021.05.035_bib46","article-title":"Low-dose CDK4\/6 inhibitors induce presentation of pathway specific MHC ligands as targets for cancer immunotherapy","author":"Charles","year":"2020","journal-title":"bioRxiv"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:23:21Z","timestamp":1778783001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"alternative-id":["S0959804921003634"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.035","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/II trial of palbociclib, pembrolizumab\u00a0and letrozole in patients with hormone receptor-positive metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}